Eurofins Amatsigroup

Their core work

Eurofins Amatsigroup is a pharmaceutical technology and contract development organization (CDMO) specializing in drug formulation, advanced delivery systems, and biopharmaceutical characterization. Their work spans the full development chain from formulation design — including nanostructured lipid carriers and polymer capsules — through pharmacokinetics and industrial scale-up. In H2020 projects, they contributed applied pharmaceutical expertise to academic consortia targeting hard-to-treat gastrointestinal conditions, translating laboratory concepts toward clinical and commercial viability. As part of the global Eurofins group, they bring analytical and development capacity that is unusual for a consortium partner: the ability to move from research prototype to scalable pharmaceutical product.

What they specialise in

How they've shifted over time

Their first project (NEW DEAL, 2017–2021) was disease-specific and molecule-specific: developing siRNA-loaded nanostructured carriers to silence JAK kinases in inflamed colon tissue, with a clear goal of industrial scale-up. By their second project (COLOTAN, 2021–2024), the focus broadened from a single therapeutic target to the underlying platform science — pharmacokinetics, PBPK modelling, gut microbiota interactions, and in vitro models for colon drug absorption. This is a recognizable CDMO trajectory: from solving one formulation problem to building generalizable capabilities and training the next generation of scientists in those methods.

They are deepening platform-level expertise in oral and colon-targeted drug delivery — moving from disease-specific formulation work toward generalizable methods (PBPK, in vitro models, microbiota), which positions them as a long-term development partner for any therapeutic targeting the GI tract.

How they like to work

Eurofins Amatsigroup participates exclusively as a consortium partner — they have not coordinated any H2020 project. This is consistent with their role as an applied industry contributor bringing specific technical services (formulation, analytics, scale-up) to academic-led research consortia. With 22 unique partners across 10 countries from just two projects, their network is broad relative to their project count, suggesting they integrate well into diverse European teams rather than anchoring a fixed circle of recurring collaborators.

In only two projects, Eurofins Amatsigroup has connected with 22 distinct partners across 10 countries, indicating genuine pan-European reach and willingness to work in heterogeneous consortia. No strong geographic concentration is apparent from the data, which is consistent with Eurofins' multinational structure.

What sets them apart

Eurofins Amatsigroup occupies a rare position among H2020 participants: a large industrial CDMO with hands-on formulation and analytical infrastructure who enters research consortia as a specialist contributor rather than seeking coordination fees. For a consortium building a drug delivery project, they offer something academic partners cannot — direct access to GMP-grade scale-up workflows, pharmacokinetics testing capacity, and a regulatory-aware development mindset. Their integration into the broader Eurofins network (one of Europe's largest testing groups) gives them analytical depth well beyond what their two EU projects alone suggest.

Highlights from their portfolio

• NEW DEAL
  The larger of their two projects (€373K), it tackled a highly specific and technically ambitious problem — siRNA nanotherapy for IBD via JAK inhibition — requiring both cutting-edge nanotechnology and a credible industrial scale-up pathway, which is where Eurofins Amatsigroup's CDMO role was essential.
• COLOTAN
  An MSCA Innovative Training Network focused on doctoral training in colon-targeted drug delivery, demonstrating that Eurofins Amatsigroup is recognized as a training-capable industry host, not just a service provider — a signal of scientific credibility in their field.